The partnership plans to market Guardant Health’s recurrence monitoring and tumor mutation profiling across all solid cancers in countries throughout the region. Credit: Shutterstock / ElpisterraThe California-based precision oncology company Guardant Health has struck a deal to promote its range of liquid and tissue biopsy tests for cancer screening across the Middle East and North African markets. Partnering with the multinational pharmaceutical company Hikma Pharmaceuticals, the partnership plans to market Guardant Health’s recurrence monitoring and tumour mutation profiling across all solid cancers in countries throughout the region. The partnership includes Guardant Health’s products such as Shield test for cancer screening and detection, Guardant Reveal for disease detection,Guardant360 and its variant TissueNext, which is intended for genomic profiling across all solid cancers. Simranjit Singh, Guardant Health Europe, the Middle East and Africa (AMEA) CEO, said: “Today, an increasing number of patients with cancer are being detected at the advanced stage, making it more crucial to match these patients to appropriate therapies in a timely manner.
